In silico screening based on predictive algorithms as a design tool for exon skipping oligonucleotides in duchenne muscular dystrophy

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Echigoya, Yusuke ^a   Mouly, Vincent ^b   Garcia, Luis ^c   Yokota, Toshifumi ^a   Duddy, William ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b SORBONNE UNIVERSITÉ   (France)

^c LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MORPHOLINO OLIGONUCLEOTIDE; OLIGONUCLEOTIDE; RNA; ANTISENSE OLIGONUCLEOTIDE; DYSTROPHIN;

ALGORITHM; ARTICLE; BINDING AFFINITY; COMPUTER MODEL; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; EXON SKIPPING; IN VITRO STUDY; MATHEMATICAL COMPUTING; PREDICTION; SCREENING; STATISTICAL MODEL; COMPUTER SIMULATION; EXON; GENETICS; HIGH THROUGHPUT SCREENING; HUMAN; RNA SPLICING;

ALGORITHMS; COMPUTER SIMULATION; DYSTROPHIN; EXONS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MODELS, STATISTICAL; MORPHOLINOS; MUSCULAR DYSTROPHY, DUCHENNE; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; RNA SPLICING;

EID: 84929467502     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0120058     Document Type: Article

References (54)

1. Wan J, Sazani P, Kole R (2009) Modification of HER2 pre-mRNA alternative splicing and its effects on breast cancer cells. Int J Cancer 124: 772-777. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2671679&tool=pmcentrez&rendertype=abstract. Accessed 7 November 2013. doi: 10.1002/ijc.24052 PMID: 19035464
2. Yilmaz-Elis AS, Aartsma-Rus A, 't Hoen PA, Safdar H, Breukel C, van Vlijmen BJ, et al. (2013) Inhibition of IL-1 Signaling by Antisense Oligonucleotide-mediated Exon Skipping of IL-1 Receptor Accessory Protein (IL-1RAcP). Mol Ther Nucleic Acids 2: e66. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3564974&tool=pmcentrez&rendertype=abstract. Accessed 7 November 2013. doi: 10.1038/mtna.2012.58 PMID: 23340324
3. Arechavala-Gomeza V, Anthony K,Morgan J, Muntoni F (2012) Antisense oligonucleotide-mediated exon skipping for Duchennemuscular dystrophy: progress and challenges. Curr Gene Ther 12: 152-160. Available: http://www.ncbi.nlm.nih.gov/pubmed/22533380. Accessed 8 November 2013. PMID: 22533380
4. Seo J, Howell MD, Singh NN, Singh RN (2013) Spinal muscular atrophy: An update on therapeutic progress. Biochim Biophys Acta 1832: 2180-2190. Available: http://www.ncbi.nlm.nih.gov/pubmed/23994186. Accessed 7 November 2013. doi: 10.1016/j.bbadis.2013.08.005 PMID: 23994186
5. Blázquez L, Aiastui A, Goicoechea M, Martins de Araujo M, Avril A, Beley C, et al. (2013) In Vitro Correction of a Pseudoexon-Generating Deep Intronic Mutation in LGMD2A by Antisense Oligonucleotides and Modified Small Nuclear RNAs. Hum Mutat 34: 1387-1395. Available: http://www.ncbi.nlm.nih.gov/pubmed/23864287. Accessed 7 November 2013. doi: 10.1002/humu.22379 PMID: 23864287
6. Gedicke-Hornung C, Behrens-Gawlik V, Reischmann S, Geertz B, Stimpel D, Weinberger F, et al. (2013) Rescue of cardiomyopathy through U7snRNA-mediated exon skipping in Mybpc3-targeted knock-in mice. EMBO Mol Med 5: 1060-1077. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3721478&tool=pmcentrez&rendertype=abstract. Accessed 7 November 2013. doi: 10.1002/emmm.201202168 PMID: 23716398
7. Rendu J, Brocard J, Denarier E, Monnier N, Piétri-Rouxel F, Beley C, et al. (2013) Exon skipping as a therapeutic strategy applied to an RYR1 mutation with pseudo-exon inclusion causing a severe core myopathy. Hum Gene Ther 24: 702-713. Available: http://www.ncbi.nlm.nih.gov/pubmed/23805838.Accessed 7 November 2013. doi: 10.1089/hum.2013.052 PMID: 23805838
8. Touznik A, Lee JJ, Yokota T (2014) New developments in exon skipping and splice modulation therapies for neuromuscular diseases. Expert Opin Biol Ther 14: 809-819. Available: http://www.ncbi.nlm.nih.gov/pubmed/24620745. Accessed 19 May 2014. doi: 10.1517/14712598.2014.896335 PMID: 24620745
9. Taniguchi-Ikeda M, Kobayashi K, Kanagawa M, Yu C, Mori K, Oda T, et al. (2011) Pathogenic exontrapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy. Nature 478: 127-131. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3412178&tool=pmcentrez&rendertype=abstract. Accessed 23 September 2014. doi: 10.1038/nature10456 PMID: 21979053
10. Hammond SM, Wood MJA (2011) Genetic therapies for RNA mis-splicing diseases. Trends Genet 27: 196-205. Available: http://www.ncbi.nlm.nih.gov/pubmed/21497936. Accessed 7 November 2013. doi: 10.1016/j.tig.2011.02.004 PMID: 21497936
11. Cirak S, Arechavala-Gomeza V, Guglieri M, Feng L, Torelli S, Anthony K, et al. (2011) Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378: 595-605. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3156980&tool=pmcentrez&rendertype=abstract. Accessed 7 November 2013. doi: 10.1016/S0140-6736(11)60756-3 PMID: 21784508
12. Goemans NM, Tulinius M, van den Akker JT, Burm BE, Ekhart PF, Heuvelmans N, et al. (2011) Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 364: 1513-1522. Available: http://www.ncbi.nlm.nih.gov/pubmed/21428760. Accessed 7 November 2013. doi: 10.1056/NEJMoa1011367 PMID: 21428760
13. R Mendell J, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP, et al. (2013) Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol. Available: http://www.ncbi.nlm.nih.gov/pubmed/23907995. Accessed 7 November 2013.
14. Emery AE (1991) Population frequencies of inherited neuromuscular diseases-a world survey. Neuromuscul Disord 1: 19-29. Available: http://www.ncbi.nlm.nih.gov/pubmed/1822774. Accessed 28 January 2013. PMID: 1822774
15. Moser H (1984) Duchenne muscular dystrophy: pathogenetic aspects and genetic prevention. Hum Genet 66: 17-40. Available: http://www.ncbi.nlm.nih.gov/pubmed/6365739. Accessed 28 January 2013. PMID: 6365739
16. Kieny P, Chollet S, Delalande P, Le Fort M, Magot A, Pereon Y, et al. (2013) Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011. Ann Phys Rehabil Med 56: 443-454. Available: http://www.ncbi.nlm.nih.gov/pubmed/23876223. Accessed 15 May 2014. doi: 10.1016/j.rehab.2013.06.002 PMID: 23876223
17. Sacco A, Mourkioti F, Tran R, Choi J, Llewellyn M, Kraft P, et al. (2010) Short telomeres and stem cell exhaustion model Duchenne muscular dystrophy in mdx/mTR mice. Cell 143: 1059-1071. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3025608&tool=pmcentrez&rendertype=abstract. Accessed 15 May 2014. doi: 10.1016/j.cell.2010.11.039 PMID: 21145579
18. Zhu C-H, Mouly V, Cooper RN, Mamchaoui K, Bigot A, Shay JW, et al. (2007) Cellular senescence in human myoblasts is overcome by human telomerase reverse transcriptase and cyclin-dependent kinase 4: consequences in aging muscle and therapeutic strategies for muscular dystrophies. Aging Cell 6: 515-523. Available: http://www.ncbi.nlm.nih.gov/pubmed/17559502. Accessed 15 May 2014. PMID: 17559502
19. Renault V, Piron-Hamelin G, Forestier C, DiDonna S, Decary S, Hentati F, et al. (2000) Skeletal muscle regeneration and the mitotic clock. Exp Gerontol 35: 711-719. Available: http://www.ncbi.nlm.nih.gov/pubmed/11053661. Accessed 15 May 2014. PMID: 11053661
20. Long C, McAnally JR, Shelton JM, Mireault AA, Bassel-Duby R, Olson EN (2014) Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA. Science 345: 1184-1188. doi: 10.1126/science.1254445 PMID: 25123483
21. Li HL, Fujimoto N, Sasakawa N, Shirai S, Ohkame T, Sakuma T, et al. (2014) Precise Correction of the Dystrophin Gene in Duchenne Muscular Dystrophy Patient Induced Pluripotent Stem Cells by TALEN and CRISPR-Cas9. Stem cell reports.
22. Fairclough RJ, Bareja A, Davies KE (2011) Progress in therapy for Duchenne muscular dystrophy. Exp Physiol 96: 1101-1113. Available: http://www.ncbi.nlm.nih.gov/pubmed/21804140. Accessed 28 January 2013. doi: 10.1113/expphysiol.2010.053025 PMID: 21804140
23. Hoffman EP, Bronson A, Levin AA, Takeda S, Yokota T, Baudy AR, et al. (2011) Restoring dystrophin expression in duchenne muscular dystrophy muscle progress in exon skipping and stop codon read through. Am J Pathol 179: 12-22. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3124804&tool=pmcentrez&rendertype=abstract. Accessed 28 January 2013. doi: 10.1016/j.ajpath.2011.03.050 PMID: 21703390
24. Partridge TA (2011) Impending therapies for Duchenne muscular dystrophy. Curr Opin Neurol 24: 415-422. Available: http://www.ncbi.nlm.nih.gov/pubmed/21892079. Accessed 29 January 2013. doi: 10.1097/WCO.0b013e32834aa3f1 PMID: 21892079
25. Pichavant C, Aartsma-Rus A, Clemens PR, Davies KE, Dickson G, Takeda S, et al. (2011) Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. Mol Ther 19: 830-840. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3098643&tool=pmcentrez&rendertype=abstract. Accessed 29 January 2013. doi: 10.1038/mt.2011.59 PMID: 21468001
26. Koenig M, Beggs AH, Moyer M, Scherpf S, Heindrich K, Bettecken T, et al. (1989) The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet 45: 498-506. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1683519&tool=pmcentrez&rendertype=abstract. Accessed 7 November 2013. PMID: 2491009
27. Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM (1988) An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2: 90-95. Available: http://www.ncbi.nlm.nih.gov/pubmed/3384440. Accessed 7 November 2013. PMID: 3384440
28. Aartsma-Rus A, van Vliet L, Hirschi M, Janson AAM, Heemskerk H, de Winter CL, et al. (2009) Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms. Mol Ther 17: 548-553. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2835096&tool=pmcentrez&rendertype=abstract. Accessed 17 October 2013. doi: 10.1038/mt.2008.205 PMID: 18813282
29. Popplewell LJ, Trollet C, Dickson G, Graham IR (2009) Design of phosphorodiamidate morpholino oligomers (PMOs) for the induction of exon skipping of the human DMD gene. Mol Ther 17: 554-561. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2835085&tool=pmcentrez&rendertype=abstract. Accessed 29 October 2013. doi: 10.1038/mt.2008.287 PMID: 19142179
30. Pramono ZAD, Wee KB, Wang JL, Chen YJ, Xiong Q Bin, Lai PS, et al. (2012) A prospective study in the rational design of efficient antisense oligonucleotides for exon skipping in the DMD gene. Hum Gene Ther 23: 781-790. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3404420&tool=pmcentrez&rendertype=abstract. Accessed 29 October 2013. doi: 10.1089/hum.2011.205 PMID: 22486275
31. Aartsma-Rus A, Houlleberghs H, van Deutekom JCT, van Ommen G-JB, 't Hoen PAC (2010) Exonic sequences provide better targets for antisense oligonucleotides than splice site sequences in the modulation of Duchenne muscular dystrophy splicing. Oligonucleotides 20: 69-77. Available: http://www.ncbi.nlm.nih.gov/pubmed/20377429. Accessed 8 September 2014. doi: 10.1089/oli.2009.0215 PMID: 20377429
32. Popplewell LJ, Malerba A, Dickson G (2012) Optimizing antisense oligonucleotides using phosphorodiamidate morpholino oligomers. Methods Mol Biol 867: 143-167. Available: http://www.ncbi.nlm.nih.gov/pubmed/22454060. Accessed 10 September 2014. doi: 10.1007/978-1-61779-767-5-10 PMID: 22454060
33. Fairbrother WG, Yeh R-F, Sharp PA, Burge CB (2002) Predictive identification of exonic splicing enhancers in human genes. Science 297: 1007-1013. Available: http://www.ncbi.nlm.nih.gov/pubmed/12114529. Accessed 16 May 2014. PMID: 12114529
34. Desmet F-O, Hamroun D, Lalande M, Collod-Béroud G, Claustres M, Béroud C (2009) Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res 37: e67. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2685110&tool=pmcentrez&rendertype=abstract. Accessed 16 May 2014. doi: 10.1093/nar/gkp215 PMID: 19339519
35. Wee KB, Pramono ZAD, Wang JL, MacDorman KF, Lai PS, Yee WC (2008) Dynamics of co-transcriptional pre-mRNA folding influences the induction of dystrophin exon skipping by antisense oligonucleotides. PLoS One 3: e1844. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2267000&tool=pmcentrez&rendertype=abstract. Accessed 29 October 2013. doi: 10.1371/journal.pone.0001844 PMID: 18365002
36. Lange SJ, Maticzka D, Möhl M, Gagnon JN, Brown CM, Backofen R (2012) Global or local? Predicting secondary structure and accessibility in mRNAs. Nucleic Acids Res 40: 5215-5226. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3384308&tool=pmcentrez&rendertype=abstract. Accessed 23 October 2013. doi: 10.1093/nar/gks181 PMID: 22373926
37. Stadler MB, Shomron N, Yeo GW, Schneider A, Xiao X, Burge CB (2006) Inference of splicing regulatory activities by sequence neighborhood analysis. PLoS Genet 2: e191. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1657047&tool=pmcentrez&rendertype=abstract. Accessed 29 October 2013. PMID: 17121466
38. Malueka RG, Takaoka Y, Yagi M, Awano H, Lee T, Dwianingsih EK, et al. (2012) Categorization of 77 dystrophin exons into 5 groups by a decision tree using indexes of splicing regulatory factors as decision markers. BMC Genet 13: 23. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3350383&tool=pmcentrez&rendertype=abstract. Accessed 29 October 2013. doi: 10.1186/1471-2156-13-23 PMID: 22462762
39. Amit M, Donyo M, Hollander D, Goren A, Kim E, Gelfman S, et al. (2012) Differential GC content between exons and introns establishes distinct strategies of splice-site recognition. Cell Rep 1: 543-556. Available: http://www.ncbi.nlm.nih.gov/pubmed/22832277. Accessed 29 October 2013. doi: 10.1016/j.celrep.2012.03.013 PMID: 22832277
40. Lorenz R, Bernhart SH, Höner Zu Siederdissen C, Tafer H, Flamm C, Stadler PF, et al. (2011) ViennaRNA Package 2.0. Algorithms Mol Biol 6: 26. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3319429&tool=pmcentrez&rendertype=abstract. Accessed 2 November 2013. doi: 10.1186/1748-7188-6-26 PMID: 22115189
41. Reuter JS, Mathews DH (2010) RNAstructure: software for RNA secondary structure prediction and analysis. BMC Bioinformatics 11: 129. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2984261&tool=pmcentrez&rendertype=abstract. Accessed 5 November 2013. doi: 10.1186/1471-2105-11-129 PMID: 20230624
42. Mamchaoui K, Trollet C, Bigot A, Negroni E, Chaouch S, Wolff A, et al. (2011) Immortalized pathological human myoblasts: towards a universal tool for the study of neuromuscular disorders. Skelet Muscle 1: 34. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3235972&tool=pmcentrez&rendertype=abstract. Accessed 4 April 2013. doi: 10.1186/2044-5040-1-34 PMID: 22040608
43. Aartsma-Rus A, De Winter CL, Janson AAM, Kaman WE, Van Ommen G-JB, Den Dunnen JT, et al. (2005) Functional analysis of 114 exon-internal AONs for targeted DMD exon skipping: indication for steric hindrance of SR protein binding sites. Oligonucleotides 15: 284-297. Available: http://www.ncbi.nlm.nih.gov/pubmed/16396622. Accessed 29 October 2013. PMID: 16396622
44. Harding PL, Fall AM, Honeyman K, Fletcher S, Wilton SD (2007) The influence of antisense oligonucleotide length on dystrophin exon skipping. Mol Ther 15: 157-166. Available: http://www.ncbi.nlm.nih.gov/pubmed/17164787. Accessed 29 October 2013. PMID: 17164787
45. Wilton SD, Fall AM, Harding PL, McClorey G, Coleman C, Fletcher S (2007) Antisense oligonucleotideinduced exon skipping across the human dystrophin gene transcript. Mol Ther 15: 1288-1296. Available: http://www.ncbi.nlm.nih.gov/pubmed/17285139. Accessed 29 October 2013. PMID: 17285139
46. Schubert S, Grünweller A, Erdmann VA, Kurreck J (2005) Local RNA target structure influences siRNA efficacy: systematic analysis of intentionally designed binding regions. J Mol Biol 348: 883-893. Available: http://www.ncbi.nlm.nih.gov/pubmed/15843020. Accessed 29 October 2013. PMID: 15843020
47. Tafer H, Ameres SL, Obernosterer G, Gebeshuber CA, Schroeder R, Martinez J, et al. (2008) The impact of target site accessibility on the design of effective siRNAs. Nat Biotechnol 26: 578-583. Available: http://www.ncbi.nlm.nih.gov/pubmed/18438400. Accessed 29 October 2013. doi: 10.1038/nbt1404 PMID: 18438400
48. Zhou H-L, Luo G, Wise JA, Lou H (2014) Regulation of alternative splicing by local histone modifications: potential roles for RNA-guided mechanisms. Nucleic Acids Res 42: 701-713. doi: 10.1093/nar/gkt875 PMID: 24081581
49. Vulin A, Barthélémy I, Goyenvalle A, Thibaud J-L, Beley C, Griffith G, et al. (2012) Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping. Mol Ther 20: 2120-2133. Available: http://www.ncbi.nlm.nih.gov/pubmed/22968479. Accessed 31 May 2013. doi: 10.1038/mt.2012.181 PMID: 22968479
50. Betts C, Saleh AF, Arzumanov AA, Hammond SM, Godfrey C, Coursindel T, et al. (2012) Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment. Mol Ther Nucleic Acids 1: e38. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3438601&tool=pmcentrez&rendertype=abstract. Accessed 8 November 2013. doi: 10.1038/mtna.2012.30 PMID: 23344180
51. Yin H, Boisguerin P, Moulton HM, Betts C, Seow Y, Boutilier J, et al. (2013) Context Dependent Effects of Chimeric Peptide Morpholino Conjugates Contribute to Dystrophin Exon-skipping Efficiency. Mol Ther Nucleic Acids 2: e124. Available: http://www.ncbi.nlm.nih.gov/pubmed/24064708. Accessed 8 November 2013. doi: 10.1038/mtna.2013.51 PMID: 24064708
52. Lehto T, Castillo Alvarez A, Gauck S, Gait MJ, Coursindel T, Wood MJA, et al. (2014) Cellular trafficking determines the exon skipping activity of Pip6a-PMO in mdx skeletal and cardiac muscle cells. Nucleic Acids Res 42: 3207-3217. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3950666&tool=pmcentrez&rendertype=abstract. Accessed 10 April 2014. doi: 10.1093/nar/gkt1220 PMID: 24366877
53. Aoki Y, Nagata T, Yokota T, Nakamura A, Wood MJA, Partridge T, et al. (2013) Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-α2 chain-null congenital muscular dystrophy mice. Hum Mol Genet 22: 4914-4928. Available: http://www.ncbi.nlm.nih.gov/pubmed/23882132. Accessed 10 April 2014. doi: 10.1093/hmg/ddt341 PMID: 23882132
54. Buratti E, Baralle M, Baralle FE (2006) Defective splicing, disease and therapy: searching for master checkpoints in exon definition. Nucleic Acids Res 34: 3494-3510. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1524908&tool=pmcentrez&rendertype=abstract. Accessed 4 November 2013. PMID: 16855287